New milestone in assessment of tissue-based biomarkers: PTEN loss as a proof-of principle in improved assessment of disease prognostication using novel biomarker quantification methods and high-throughput automated detection on digital images using artificial intelligence.

Despite prostate cancer being one of the most commonly diagnosed diseases in men, the road to finding the cure is still hindered by several challenges. Successful management of post-operative patients is directly related to the accurate diagnosis and prognostication of prostate cancer. Over the years, many researchers around the world have put forward numerous molecular markers to aid in this process. However, none of these markers have been translated into clinical practice. Lack of conclusive data and subjectivity in the assessment of these molecular markers are some of the main reasons behind this.